News

Filter

New analysis of potential savings from Biosimilars in USA

New analysis of potential savings from Biosimilars in USA

04-11-2014

Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such…

Anti-Arthritics/RheumaticsBiosimilarsFinancialGenericsOncologyRegulationSandozUSA

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Sandoz moves forward with development of biosimilar rituximab, Roche’s blockbuster RA drug

11-01-2011

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX) Sandoz says that it has begun a Phase…

Anti-Arthritics/RheumaticsBiotechnologyGenericsMabTheraNovartisPharmaceuticalResearchRituxanrituximabRocheSandoz

Back to top